A Phase I, Open-Label Study to Determine Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of SH3765 Tablet in Patients With Advanced Malignant Tumor
Latest Information Update: 24 Sep 2021
At a glance
- Drugs SH 3765 (Primary)
- Indications Adenoid cystic carcinoma; Advanced breast cancer; Carcinoma; Diffuse large B cell lymphoma; Head and neck cancer; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Nanjing Sanhome Pharmaceutical
- 25 Aug 2021 New trial record